Study of DXC006 for advanced solid tumors and blood cancers
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug, DXC006, for people with advanced solid tumors or blood cancers like multiple myeloma and neuroblastoma that have not responded to standard treatments. The goal is to see if it is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older
- You have a solid tumor or blood cancer that standard treatments did not help
- You can provide a tumor tissue sample for testing
- Your overall health status is fair to good (ECOG score 0-2)
- Your major organs (bone marrow, liver, kidneys, heart) are working adequately
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called DXC018 for people with advanced solid tumors that have not responded to standard treatments or for whom no standard treatment exists. The goal is to see if the drug can shrink or slow the growth of these tumors.
This trial tests a new drug called CBX-663 in people with certain blood cancers, solid tumors, or glioblastoma that have returned or not responded to standard treatment. It aims to see if the drug is safe and helps shrink or control the cancer.
This early-phase trial tests a new drug (CD-001) for people with advanced solid tumors. It will check if the drug is safe, how the body handles it, and if it helps shrink tumors.
This trial tests a new drug called HDM2006 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and effective.
This trial tests DXC014, a new drug, in people with advanced solid tumors, including prostate cancer. It aims to see if the drug is safe and effective.
This trial tests a new drug called DXC008 for people with advanced solid tumors, including prostate cancer, that have not responded to standard treatments. The goal is to see if it can help shrink tumors or slow their growth.
Hear when a new Hematological Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.